Clinical, Laboratory, and Bone Marrow Findings of 31 Patients With Waldenström Macroglobulinemia.

Szczegóły
Abstrakt

Tytuł:: Clinical, Laboratory, and Bone Marrow Findings of 31 Patients With Waldenström Macroglobulinemia.
Autorzy:: Ahn A; Department of Laboratory Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Park CJ; Department of Laboratory Medicine, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea. .
Cho YU; Department of Laboratory Medicine, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea.
Jang S; Department of Laboratory Medicine, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea.
Seo EJ; Department of Laboratory Medicine, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea.
Lee JH; Department of Internal Medicine, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea.
Yoon DH; Department of Internal Medicine, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea.
Suh C; Department of Internal Medicine, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea.
Źródło:: Annals of laboratory medicine [Ann Lab Med] 2020 May; Vol. 40 (3), pp. 193-200.
Typ publikacji:: Journal Article
Język:: English
Imprint Name(s):: Original Publication: Seoul : Korean Society for Laboratory Medicine
MeSH Terms:: Bone Marrow/*pathology
Waldenstrom Macroglobulinemia/*diagnosis
Aged ; Aged, 80 and over ; Antigens, CD20/metabolism ; B-Lymphocytes/cytology ; B-Lymphocytes/metabolism ; Bone Marrow/metabolism ; CD40 Ligand/metabolism ; Diagnosis, Differential ; Flow Cytometry/methods ; Humans ; Immunophenotyping ; Kaplan-Meier Estimate ; Mast Cells/cytology ; Mast Cells/metabolism ; Middle Aged ; Paraproteinemias/complications ; Paraproteinemias/diagnosis ; Plasma Cells/cytology ; Plasma Cells/metabolism ; Retrospective Studies ; Waldenstrom Macroglobulinemia/complications ; Waldenstrom Macroglobulinemia/mortality
References:: Zhonghua Bing Li Xue Za Zhi. 2010 May;39(5):308-12. (PMID: 20654153)
Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):99-102. (PMID: 21454203)
Microsc Res Tech. 2003 Jan 1;60(1):64-9. (PMID: 12500262)
Ann Intern Med. 1978 Jun;88(6):753-7. (PMID: 666133)
Br J Haematol. 2013 Aug;162(3):295-303. (PMID: 23651417)
Am J Clin Pathol. 1995 Nov;104(5):517-23. (PMID: 7572811)
Ann Oncol. 2006 Aug;17(8):1275-82. (PMID: 16788002)
Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):103-5. (PMID: 21454204)
J Clin Exp Hematop. 2014;54(2):103-10. (PMID: 25318942)
Br J Haematol. 2002 Oct;119(1):122-4. (PMID: 12358914)
Clin Lymphoma Myeloma Leuk. 2013 Dec;13(6):700-3. (PMID: 24070824)
Neth J Med. 2013 Mar;71(2):90-6. (PMID: 23462060)
Ann Clin Lab Sci. 2015 Fall;45(5):593-7. (PMID: 26586715)
Clin Lymphoma Myeloma. 2006 May;6(6):478-83. (PMID: 16796779)
Am J Clin Pathol. 1981 Jan;75(1):34-8. (PMID: 7457427)
Hematol Oncol. 2013 Jun;31 Suppl 1:76-80. (PMID: 23775655)
Exp Hematol. 2017 Jan;45:56-63. (PMID: 27693387)
Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):218-21. (PMID: 23490994)
J Clin Gastroenterol. 2002 Feb;34(2):147-9. (PMID: 11782609)
Am J Clin Pathol. 2001 Sep;116(3):420-8. (PMID: 11554171)
Am J Med. 1982 Oct;73(4):539-42. (PMID: 6957149)
Nature. 1993 Sep 23;365(6444):340-3. (PMID: 7690905)
Ann Intern Med. 1966 Apr;64(4):856-60. (PMID: 23841206)
Am J Hematol. 2003 Aug;73(4):273-5. (PMID: 12879432)
Am J Clin Pathol. 2007 Feb;127(2):176-81. (PMID: 17210522)
Trends Immunol. 2004 May;25(5):235-41. (PMID: 15099563)
Am J Hematol. 2017 Feb;92(2):209-217. (PMID: 28094456)
Arch Pathol Lab Med. 2013 Apr;137(4):580-5. (PMID: 23544948)
J Clin Invest. 1997 Apr 1;99(7):1492-9. (PMID: 9119992)
Hum Pathol. 1998 Sep;29(9):1021-4. (PMID: 9744322)
Leukemia. 2002 Oct;16(10):1992-2003. (PMID: 12357350)
Contributed Indexing:: Keywords: CD154; Mast cell; Monoclonal gammopathy; Waldenström macroglobulinemia
Substance Nomenclature:: 0 (Antigens, CD20)
147205-72-9 (CD40 Ligand)
Entry Date(s):: Date Created: 20191221 Date Completed: 20200527 Latest Revision: 20200527
Update Code:: 20240105
PubMed Central ID:: PMC6933056
DOI:: 10.3343/alm.2020.40.3.193
PMID:: 31858758
: Czasopismo naukowe

Background: Waldenström macroglobulinemia (WM) is a subset of lymphoplasmacytic lymphoma (LPL) with bone marrow (BM) involvement and an IgM monoclonal gammopathy of any level. We aimed to identify the clinical, laboratory, and BM findings of patients with WM and to evaluate the usefulness of CD154 for the diagnosis and prognosis of WM.
Methods: We reviewed the medical records and BM studies and/or flow cytometric immunotyping of 31 patients with untreated WM. Semiquantitative immunohistochemistry (CD20, CD138, tryptase, and CD154) of BM was performed.
Results: Only six patients presented with symptoms of hyperviscosity syndrome. Eleven patients had solid cancer and/or another hematologic malignancy. Mast cells (MC) increased in all samples, with some in close contact with tumor cells. Tryptase-positive MC (17.1/ high-power fields [HPF], 1.2-72.0/HPF) and CD154-positive MC (8.6/HPF, 0.1-31.1/HPF) were observed. The high CD154-positive MC (≥8.6/HPF) group showed a lower overall five-year survival rate than the low CD154-positive MC (<8.6/HPF) group (71.9% vs. 100.0%; P =0.012). Flow cytometric immunophenotyping of BM aspirates showed increased B lymphocytes and plasma cells with a normal phenotype (CD138⁺/CD38⁺/CD19⁺/CD45⁺/CD56⁻).
Conclusions: Approximately one third of WM patients showed other malignancies and all patients had increased MC. Immunohistochemistry and flow cytometric immunophenotyping are useful for diagnosing WM, and increased CD154-positive MC can indicate poor prognosis.
Competing Interests: None declared.
(© The Korean Society for Laboratory Medicine.)

Informacja